The molecular basis of the anticancer effect of statins.
Big data
Drug repurposing
Metastases
Statins
Synthetic lethality
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
03
06
2024
accepted:
26
08
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
31
8
2024
Statut:
epublish
Résumé
Statins, widely used cardiovascular drugs that lower cholesterol by inhibiting HMG-CoA reductase, have been increasingly recognized for their potential anticancer properties. This study elucidates the underlying mechanism, revealing that statins exploit Synthetic Lethality, a principle where the co-occurrence of two non-lethal events leads to cell death. Our computational analysis of approximately 37,000 SL pairs identified statins as potential drugs targeting genes involved in SL pairs with metastatic genes. In vitro validation on various cancer cell lines confirmed the anticancer efficacy of statins. This data-driven drug repurposing strategy provides a molecular basis for the anticancer effects of statins, offering translational opportunities in oncology.
Identifiants
pubmed: 39217242
doi: 10.1038/s41598-024-71240-6
pii: 10.1038/s41598-024-71240-6
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20298Subventions
Organisme : HORIZON EUROPE European Research Council
ID : 101053122
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33. https://doi.org/10.3322/caac.21708 (2022).
doi: 10.3322/caac.21708
pubmed: 35020204
Horowitz, M., Neeman, E., Sharon, E. & Ben-Eliyahu, S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol. 12(4), 213–226. https://doi.org/10.1038/nrclinonc.2014.224 (2015).
doi: 10.1038/nrclinonc.2014.224
pubmed: 25601442
pmcid: 5497123
Koval, L., Proshkina, E., Shaposhnikov, M. & Moskalev, A. The role of DNA repair genes in radiation-induced adaptive response in drosophila melanogaster is differential and conditional. Biogerontology 21(1), 45–56. https://doi.org/10.1007/s10522-019-09842-1 (2019).
doi: 10.1007/s10522-019-09842-1
pubmed: 31624983
Jabbour, S. K. et al. Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 92(3), 627–633. https://doi.org/10.1016/j.ijrobp.2015.02.017 (2015).
doi: 10.1016/j.ijrobp.2015.02.017
pubmed: 26068495
pmcid: 5767471
Corrie, P. G. Cytotoxic chemotherapy: Clinical aspects. Medicine 36(1), 24–28. https://doi.org/10.1016/j.mpmed.2007.10.012 (2008).
doi: 10.1016/j.mpmed.2007.10.012
Kilmister, E. J., Koh, S. P., Weth, F. R., Gray, C. & Tan, S. T. Cancer metastasis and treatment resistance: Mechanistic insights and therapeutic targeting of cancer stem cells and the tumor microenvironment. Biomedicines 10(11), 2988. https://doi.org/10.3390/biomedicines10112988 (2022).
doi: 10.3390/biomedicines10112988
pubmed: 36428556
pmcid: 9687343
Olivier, T., Haslam, A. & Prasad, V. Anticancer drugs approved by the us food and drug administration from 2009 to 2020 according to their mechanism of action. JAMA Netw. Open 4(12), 2138793. https://doi.org/10.1001/jamanetworkopen.2021.38793 (2021).
doi: 10.1001/jamanetworkopen.2021.38793
Hadiloo, K., Tahmasebi, S. & Esmaeilzadeh, A. CAR-NKT cell therapy: A new promising paradigm of cancer immunotherapy. Cancer Cell Int. 23(1), 86. https://doi.org/10.1186/s12935-023-02923-9 (2023).
doi: 10.1186/s12935-023-02923-9
pubmed: 37158883
pmcid: 10165596
Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances. Mol. Cancer 22(1), 20. https://doi.org/10.1186/s12943-023-01723-z (2023).
doi: 10.1186/s12943-023-01723-z
pubmed: 36717905
pmcid: 9885707
Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. https://doi.org/10.1038/s41591-023-02767-w (2024).
doi: 10.1038/s41591-023-02767-w
pubmed: 38266761
Topatana, W. et al. Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation. J. Hematol. Oncol. 13(1), 1–22. https://doi.org/10.1186/s13045-020-00956-5 (2020).
doi: 10.1186/s13045-020-00956-5
Zhang, B. et al. The tumor therapy landscape of synthetic lethality. Nat. Commun. 12(1), 1275. https://doi.org/10.1038/s41467-021-21544-2 (2021).
doi: 10.1038/s41467-021-21544-2
pubmed: 33627666
pmcid: 7904840
Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185(3), 563–575 (2022).
doi: 10.1016/j.cell.2022.01.003
pubmed: 35120664
pmcid: 9147702
Gambardella, V. et al. Personalized medicine: Recent progress in cancer therapy. Cancers 12(4), 1009. https://doi.org/10.3390/cancers12041009 (2020).
doi: 10.3390/cancers12041009
pubmed: 32325878
pmcid: 7226371
O’Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18(10), 613–623. https://doi.org/10.1038/nrg.2017.47 (2017).
doi: 10.1038/nrg.2017.47
pubmed: 28649135
Kaitin, K. I. Deconstructing the drug development process: The new face of innovation. Clin. Pharmacol. Ther. 87(3), 356–361. https://doi.org/10.1038/clpt.2009.293 (2010).
doi: 10.1038/clpt.2009.293
pubmed: 20130565
Hua, Y. et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. Eur. J. Med. Chem. 234, 114239. https://doi.org/10.1016/j.ejmech.2022.114239 (2022).
doi: 10.1016/j.ejmech.2022.114239
pubmed: 35290843
pmcid: 8883737
Abdelsayed, M., Kort, E. J., Jovinge, S. & Mercola, M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat. Rev. Cardiol. 19(11), 751–764. https://doi.org/10.1038/s41569-022-00717-6 (2022).
doi: 10.1038/s41569-022-00717-6
pubmed: 35606425
pmcid: 9125554
Santamaría, L. P. et al. A data-driven methodology towards evaluating the potential of drug repurposing hypotheses. Comput. Struct. Biotechnol. J. 19, 4559–4573 (2021).
doi: 10.1016/j.csbj.2021.08.003
Flanary, V. L., Fisher, J. L., Wilk, E. J., Howton, T. C. & Lasseigne, B. N. Computational advancements in drug repurposing for cancer combination therapy prediction. JCO Precis. Oncol. 7, e2300261. https://doi.org/10.20944/preprints202305.1637.v1 (2023).
doi: 10.20944/preprints202305.1637.v1
pubmed: 37824797
US Food and Drug Amministration: Drug Approvals and Databases (2022). https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases .
Schein, C. H. Repurposing approved drugs for cancer therapy. Br. Med. Bull. 137(1), 13–27. https://doi.org/10.1093/bmb/ldaa045 (2021).
doi: 10.1093/bmb/ldaa045
pubmed: 33517358
pmcid: 7929227
Urquhart, L. Top drugs and companies by sales in 2018. Nat. Rev. Drug Discov. https://doi.org/10.1038/d41573-019-00049-0 (2019).
doi: 10.1038/d41573-019-00049-0
pubmed: 31673140
Borgquist, S., Broberg, P., Tojjar, J. & Olsson, H. Statin use and breast cancer survival—A Swedish nationwide study. BMC Cancer 19(1), 1–9. https://doi.org/10.1186/s12885-018-5263-z (2019).
doi: 10.1186/s12885-018-5263-z
Wang, Q. et al. Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta-analysis. Oncol. Lett. 25(2), 65. https://doi.org/10.3892/ol.2022.13648 (2022).
doi: 10.3892/ol.2022.13648
pubmed: 36644149
pmcid: 9827460
Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401–404 (2012).
doi: 10.1158/2159-8290.CD-12-0095
pubmed: 22588877
...Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548(7667), 297–303. https://doi.org/10.1038/nature23306 (2017).
doi: 10.1038/nature23306
pubmed: 28783718
pmcid: 5995337
Chakravarty, D. et al. Oncokb: A precision oncology knowledge base. JCO Precis. Oncol 1, 1–16 (2017).
doi: 10.1200/PO.17.00011
Zhong, L., Zhao, Z. & Zhang, X. Genetic differences between primary and metastatic cancer: A pan-cancer whole-genome comparison study. Signal Transduct. Target. Therapy 8(1), 363. https://doi.org/10.1038/s41392-023-01596-0 (2023).
doi: 10.1038/s41392-023-01596-0
Wang, J. et al. SynLethDB 2.0: A web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. Database 2022, baac030. https://doi.org/10.1093/database/baac030 (2022).
doi: 10.1093/database/baac030
pubmed: 35562840
pmcid: 9216587
Piñeiro-Yáñez, E. et al. PanDrugs: A novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Med. 10(1), 1–11. https://doi.org/10.1186/s13073-018-0546-1 (2018).
doi: 10.1186/s13073-018-0546-1
Zagidullin, B. et al. DrugComb: An integrative cancer drug combination data portal. Nucleic Acids Res. 47(W1), 43–51. https://doi.org/10.1093/nar/gkz337 (2019).
doi: 10.1093/nar/gkz337
Erridge, P. The pareto principle. Br. Dent. J. 201(7), 419–419. https://doi.org/10.1038/sj.bdj.4814131 (2006).
doi: 10.1038/sj.bdj.4814131
pubmed: 17031332
Cafforio, P., Dammacco, F., Gernone, A. & Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26(5), 883–891. https://doi.org/10.1093/carcin/bgi036 (2005).
doi: 10.1093/carcin/bgi036
pubmed: 15705602
Zahedipour, F., Butler, A. E., Rizzo, M. & Sahebkar, A. Statins and angiogenesis in non-cardiovascular diseases. Drug Discov. Today 27(10), 103320. https://doi.org/10.1016/j.drudis.2022.07.005 (2022).
doi: 10.1016/j.drudis.2022.07.005
pubmed: 35850434
Jin, H. et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 9(1), 265–278. https://doi.org/10.7150/thno.27246 (2019).
doi: 10.7150/thno.27246
pubmed: 30662566
pmcid: 6332796
Guerrab, A. E. et al. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget 7(45), 73618–73637. https://doi.org/10.18632/oncotarget.12037 (2016).
doi: 10.18632/oncotarget.12037
pubmed: 27655662
pmcid: 5342003
Pedersen, T. R. & Tobert, J. A. Simvastatin: A review. Expert Opin. Pharmacother. 5(12), 2583–2596. https://doi.org/10.1517/14656566.5.12.2583 (2004).
doi: 10.1517/14656566.5.12.2583
pubmed: 15571475
Inasu, M., Feldt, M., Jernström, H., Borgquist, S. & Harborg, S. Statin use and patterns of breast cancer recurrence in the Malmö diet and cancer study. Breast 61, 123–128. https://doi.org/10.1016/j.breast.2022.01.003 (2022).
doi: 10.1016/j.breast.2022.01.003
pubmed: 34995921
pmcid: 8741597
Editors of Nature Methods. Computation and biology: A partnership. Nat. Methods 18(7), 695–695. https://doi.org/10.1038/s41592-021-01215-2 (2021).
doi: 10.1038/s41592-021-01215-2
Schäffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E. & Lee, J. S. A systematic analysis of the landscape of synthetic lethality-driven precision oncology. Med 5(1), 73–89 (2024).
doi: 10.1016/j.medj.2023.12.009
pubmed: 38218178
Testa, C., Pidò, S., Jacchetti, E., Raimondi, M. T., Ceri, S. & Pinoli, P. Inference of synthetically lethal pairs of genes involved in metastatic processes via non-negative matrix tri-factorization. In Proceedings of the 2023 15th International Conference on Bioinformatics and Biomedical Technology 47–53 (2023).
Majidi, A., Na, R., Jordan, S. J., De Fazio, A. & Webb, P. M. Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. Int. J. Cancer 148(7), 1608–1615. https://doi.org/10.1002/ijc.33333 (2020).
doi: 10.1002/ijc.33333
pubmed: 33034053
Couttenier, A. et al. Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLoS ONE 12(12), 0189233. https://doi.org/10.1371/journal.pone.0189233 (2017).
doi: 10.1371/journal.pone.0189233
Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343(6257), 425–430. https://doi.org/10.1038/343425a0 (1990).
doi: 10.1038/343425a0
pubmed: 1967820
Park, S.-Y. & Kim, J.-S. A short guide to histone deacetylases including recent progress on class II enzymes. Exp. Mol. Med. 52(2), 204–212 (2020).
doi: 10.1038/s12276-020-0382-4
pubmed: 32071378
pmcid: 7062823
Deng, C.-X. Roles of BRCA1 in DNA damage repair: A link between development and cancer. Hum. Mol. Genet. 12(90001), 113–123. https://doi.org/10.1093/hmg/ddg082 (2003).
doi: 10.1093/hmg/ddg082
Fu, X., Tan, W., Song, Q., Pei, H. & Li, J. BRCA1 and breast cancer: Molecular mechanisms and therapeutic strategies. Front. Cell Dev. Biol. 10, 813457. https://doi.org/10.3389/fcell.2022.813457 (2022).
doi: 10.3389/fcell.2022.813457
pubmed: 35300412
pmcid: 8921524
Armstrong, N., Ryder, S., Forbes, C., Ross, J. & Quek, R. G. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin. Epidemiol. 11, 543–561. https://doi.org/10.2147/clep.s206949 (2019).
doi: 10.2147/clep.s206949
pubmed: 31372057
pmcid: 6628947
Bu, H. et al. BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group. J. Obstet. Gynaecol. Res. 45(11), 2267–2274. https://doi.org/10.1111/jog.14090 (2019).
doi: 10.1111/jog.14090
pubmed: 31411802
Neumann, J., Zeindl-Eberhart, E., Kirchner, T. & Jung, A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205(12), 858–862. https://doi.org/10.1016/j.prp.2009.07.010 (2009).
doi: 10.1016/j.prp.2009.07.010
pubmed: 19679400
Vodithala, S. & Bhake, A. Detection of KRAS mutations in triple-negative breast cancers by polymerase chain reaction. J. Datta Meghe Inst. Med. Sci. Univ. 19(1), 71–76. https://doi.org/10.4103/jdmimsu.jdmimsu_703_23 (2024).
doi: 10.4103/jdmimsu.jdmimsu_703_23
Bjorkhem-Bergman, L., Lindh, J. D. & Bergman, P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects?. Br. J. Clin. Pharmacol. 72(1), 164–165. https://doi.org/10.1111/j.1365-2125.2011.03907.x (2011).
doi: 10.1111/j.1365-2125.2011.03907.x
pubmed: 21223360
pmcid: 3141200
Jiang, P. et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br. J. Cancer 111(8), 1562–1571. https://doi.org/10.1038/bjc.2014.431 (2014).
doi: 10.1038/bjc.2014.431
pubmed: 25093497
pmcid: 4200085
Duong, H. & Bajaj, T. Lovastatin. In StatPearls [Internet]. Treasure Island (FL): StatPearls (2023).
Talreja, O., Kerndt, C.C. & Cassagnol, M. Simvastatin. In StatPearls [Internet]. Treasure Island (FL): StatPearls (2023).